GENE ONLINE|News &
Opinion
Blog

Seagen
GeneOnline’s Pick: Top 10 Global Industry News Stories in 2023 (Part 1)
2024-01-08
Reviewing the Market Trends in the Antibody-Drug Conjugate Development: A Focus on Roche, Sanofi, BMS, Seagen, and BioNTech
2024-01-05
Pfizer Acquires Seagen for $43 Billion to Capture Leading Position in Oncology
2023-03-14
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Priority Review of Seagen’s Colorectal Cancer Treatment Wins FDA Acceptance
2022-09-19
Merck Reportedly Interested in Potential $40 Billion SeaGen Buyout
2022-07-08
Astellas, Seagen Cancer Drug Becomes First and Only Approved ADC For Advanced Urothelial Cancer in Japan
2021-09-28
Seagen, Genmab’s Antibody Drug Conjugate Bags FDA Approval for Cervical Cancer
2021-09-22
Seagen Licenses ADC Asset From a Chinese Player to Disrupt HER2 Market
2021-08-10
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top